Infections due to Neisseria gonorrhoeae are the second most commonly reported infection in the United States and are a global public health priority [1] . Complications and sequelae of gonococcal infections include pelvic inflammatory disease, infertility, ectopic pregnancy, chronic pelvic pain, infection of children born to infected mothers, and increased risk for human immunodeficiency virus (HIV) infection in exposed persons. Recently, continuing and progressive development of antimicrobial resistance has led the US Centers for Disease Control and Prevention to narrow recommended therapy for gonorrhea treatment to a single regimen consisting of an injectable cephalosporin antibiotic, ceftriaxone (250 mg), administered concomitantly with a single, 1.0-g oral dose of azithromycin [2] [3] [4] . Progressively declining susceptibility to cephalosporins, however, is already well documented [2, 4] . Thus, given the inexorably progressive nature of gonococcal antimicrobial resistance development, as well as the fact that approximately 10% of Americans may report allergy to β-lactam antibiotics [5] and therefore may not be readily treated with cephalosporin antibiotics, new, non-β-lactam antibiotics are sorely needed for treatment of gonorrhea. Single-dose therapy with 2.0 g of azithromycin, an azalide antimicrobial in the macrolide class, is recommended as alternative therapy for gonorrhea treatment in patients who cannot receive ceftriaxone [3] . Use of this regimen, however, is limited by the fact that both increasing and rapid acquisition of azithromycin resistance have been described [6, 7] and that some persons taking azithromycin will experience adverse gastrointestinal events [8] .
Solithromycin (CEM-101) is a novel oral fluoroketolide antimicrobial that acts at multiple target sites on the bacterial ribosome [9, 10] . The drug has substantial in vitro activity against N. gonorrhoeae, including gonococcal strains resistant to azithromycin [11] . In addition, solithromycin has in vitro activity against other sexually transmitted pathogens including Chlamydia trachomatis and Mycoplasma genitalium [10, 11] . Based on these promising preliminary data, we carried out a 2-center, phase 2 trial evaluating the safety and efficacy of 2 doses of solithromycin (1200 mg and 1000 mg) as oral single-dose therapy for treatment of uncomplicated urogenital infections.
METHODS

Study Design
This study was a 2-center, open-label, noncomparative phase 2 trial involving men and women with uncomplicated urogenital gonorrhea and was conducted from May 2012 through June 2013. The trial was designed to provide initial human data on the utility of single-dose oral solithromycin for treatment of uncomplicated urogenital gonorrhea as well as to add information regarding the safety of the drug to the safety data collected as part of larger, ongoing clinical trials using multiple doses of solithromycin to treat community-acquired pneumonia. The study protocol and procedures were reviewed and approved by investigational review boards at the Alabama State Department of Health, the University of Alabama at Birmingham, and the University of Washington. All subjects provided written consent for participation.
Participants
Patients were initially eligible for study inclusion if they (1) were suspected to be infected with urethral or cervical N. gonorrhoeae (defined as untreated urethral or cervical N. gonorrhoeae identified by Gram stain demonstrating gram-negative intracellular diplococci, a culture or nucleic acid amplification test [NAAT] performed within the preceding 2 weeks indicating gonorrhea, or sexual contact in the past 21 days with a partner diagnosed with gonorrhea [women only]); and (2) were willing to abstain from sexual intercourse or to use condoms until follow-up was complete, and were willing and able to swallow 5-6 solithromycin capsules intact. Pregnancy tests were completed for all women, and pregnant women were not enrolled. Participants were excluded from the trial if they had suspected complicated or systemic gonococcal infection ( pelvic inflammatory disease, disseminated gonococcal infection, etc); were known to have a concurrent infection requiring antimicrobial therapy; had a reported allergy to macrolide antibiotics; had a known condition that could affect oral absorption of the drug; were known to have HIV or chronic hepatitis B or C infection; had used systemic or intravaginal antibiotics within the 30 days preceding study enrollment; had genital ulcer disease at the time of presentation; had an electrocardiographic QTc interval >450 msec in men or >470 msec in women or were taking medications known to prolong the QT interval; had known significant renal, hepatic, or hematologic impairment; were chronically immunosuppressed, had recently taken immunosuppressive medications, or had received a solid organ transplant; or had any concomitant condition that, in the opinion of the investigators, would hinder evaluation of response to therapy.
Participant Evaluation and Therapy
At enrollment and following receipt of informed consent for study participation, all subjects underwent a directed physical examination and specimen collection, had an electrocardiogram performed, had blood drawn for serologic testing as per clinic protocol and for clinical chemistry and hematologic evaluations, and performed first-catch urine collection for urinalysis and for storage and future M. genitalium testing. In men, a urethral Gram stain was routinely performed at the time of enrollment. Irrespective of exposure history, swab specimens were obtained for gonococcal culture and gonococcal and chlamydial NAATs (Hologic/Gen-Probe Aptima Combo 2) from the oropharynx, urethra (men) or cervix (women), and rectum. Following clinical assessment, participants were treated with either solithromycin 1200 mg (six 200-mg capsules) or 1000 mg (five 200-mg capsules) under direct observation. The initial 28 consecutively enrolled participants were treated with 1200 mg of solithromycin and, subsequently, the final 31 participants were treated with a single 1000-mg dose of the drug.
Participants were instructed to return for follow-up evaluation 7 days after enrollment; only those who returned between 7 and 10 days were evaluable for therapeutic efficacy and for follow-up assessment for adverse clinical or laboratory events. At the time of follow-up, an interval history was taken to assess clinical response to therapy (symptom resolution) and possible adverse events, and repeat directed physical examination, specimen collection for culture and NAAT testing, and venous blood and urine collections were performed. Subjects were reimbursed for their time and effort in study participation at the time of the follow-up visit.
Microbiologic Evaluation
Specimens collected for gonococcal culture were immediately plated onto modified Thayer-Martin medium and incubated at 35°C in a 4%-7% carbon dioxide environment. The identity of all gonococcal isolates was confirmed using standard methods. All N. gonorrhoeae isolated underwent antimicrobial susceptibility testing to solithromycin, azithromycin, ceftriaxone, cefixime, doxycycline, penicillin, and ciprofloxacin by agar dilution antimicrobial susceptibility testing. Results were interpreted according to Clinical and Laboratory Standards Institute criteria [12] .
In addition to culture specimens collected at the time of enrollment, NAATs (Gen-Probe/Hologic Aptima Combo 2) from urogenital sites, the pharynx and rectum for N. gonorrhoeae and C. trachomatis were also performed according to the manufacturer's instructions on all participants, irrespective of exposure history. Urine specimens from all participants were tested centrally for the presence of M. genitalium using the Gen-Probe transcription mediated amplification-hybridization protection assay M. genitalium analyte-specific reagent assay at the Louisiana State University Sexually Transmitted Disease Research Laboratory (David H. Martin, MD, Director) [13] .
Data Management, Analyses, and Trial Outcomes
Clinical and laboratory data were electronically entered into an electronic case report form. Data management was conducted by DATARAK Clinical and Consulting Services. The study's primary efficacy outcome measure was the microbiologic outcome based on culture results from specimens collected at the test of cure visit, 7-10 days after study drug administration. Safety analysis was performed on all patients who received solithromycin, irrespective of microbiologic results. Secondary microbiologic analyses included clearance of gonococcal, chlamydial, and M. genitalium nucleic acids from participants with positive tests for those organisms at enrollment. The trial was registered at ClinicalTrials.gov prior to initiation (NCT01591447).
RESULTS
Patient Population
A total of 59 participants were enrolled and treated in this trial; 28 participants received 1200 mg of solithromycin and 31 participants received 1000 mg. The mean age of participants was 27.1 years; 32 (54%) were male, and 47 (80%) were black (Table 1) . Forty-two (71%) participants reported sex with opposite-sex partners, 12 (20%) reported same-sex partners, and 5 (8%) reported sex with both men and women. All participants who acknowledged sexual contact with same-sex partners were male.
Treatment Outcomes
Although this study was initially designed to evaluate the 1200-mg dose of solithromycin, given the 100% efficacy and relatively frequent gastrointestinal side effects that accompanied the 1200-mg dose, following enrollment of participants to receive the 1200-mg dose of solithromycin, the study was modified to evaluate additional participants treated with a 1000-mg dose to assess impact on side effects and efficacy. In all, 46 (78%) participants had positive cultures for N. gonorrhoeae at the time of enrollment: 24 of the 28 (86%) persons who received 1200 mg of oral solithromycin and 22 of 31 (71%) who received 1000 mg. Among the 22 participants with positive urogenital cultures treated with 1200 mg, there were also 4 positive pharyngeal cultures (1 men, 3 women) and 1 positive rectal culture (a woman). For the 20 participants treated with 1000 mg, among participants with positive urogenital cultures, 2 subjects had a positive rectal culture (both women) and 1 had a positive pharyngeal culture (a man). In addition, among the 46 participants with positive gonorrhea cultures, in 4 participants only extragenital sites (3 pharyngeal, 1 rectal) were culture positive for N. gonorrhoeae. Following therapy, cultures for N. gonorrhoeae from all sites of infection were negative for all participants treated with either the 1200-mg or the 1000-mg dose of solithromycin at all 54 sites of culture-proven infection (Table 2) .
In addition to culture, all participants in the study were also tested using NAATs for infection at all potential sites of sexual exposure (ie, urethra for men or cervix for women, pharynx, and rectum), irrespective of exposure history. As might be anticipated, the highly sensitive NAAT assay detected more infections, particularly at extragenital ( pharyngeal and rectal) sites (Table 2) . Among participants treated with either of the solithromycin doses, the corresponding gonococcal NAATs were positive in all 46 participants with positive cultures. No participant with a negative urogenital culture had a positive urogenital NAAT. In contrast, whereas pharyngeal cultures detected a total of just 8 infections prior to therapy, pharyngeal NAATs were positive in 16 participants. Similarly, while rectal cultures for N. gonorrhoeae were positive in just 4 study participants prior to therapy, NAATs were positive in 20. Among participants with positive extragenital gonococcal NAATs, these were the only positive tests in a total of 4 participants with pharyngeal infections only (2 men and 2 women). No patient with positive rectal NAAT specimens for N. gonorrhoeae had negative tests for urogenital infection. Reflecting the welldescribed tendency of NAATs to detect residual nucleic acids following therapy [13, 14] , at follow-up, NAATs for gonococcal nucleic acids were positive in 5 (12.2%) specimens taken from the 41 sites, with positive pretreatment tests in the 1200-mg solithromycin group and 5 of 37 (13.5%) specimens from sites that were gonococcal NAAT positive prior to treatment among participants receiving the 1000-mg dose (Table 2) .
Chlamydial and M. genitalium Coinfection
Urogenital specimens collected from all participants were also tested for the presence of C. trachomatis and M. genitalium using NAATs. At 1 week of follow-up, NAATs for C. trachomatis had become negative in 7 of 8 (87.5%) participants with positive C. trachomatis NAATs who received 1200 mg of solithromycin (1 participant had both urogenital and rectal infection) and 2 of 3 (66%) who received 1000 mg. Similarly, singledose solithromycin was associated with clearance of M. genitalium nucleic acids in 6 of 7 (86.7%) participants in the 1200-mg treatment group and from 1 of 3 (33%) in the 1000-mg group.
In Vitro Susceptibility Testing
From the 59 enrolled participants, 47 pretreatment N. gonorrhoeae isolates were available for antimicrobial susceptibility testing ( participants with pharyngeal or rectal infections may have contributed >1 pretreatment isolate). Minimum inhibitory concentrations for solithromycin ranged from <0.008 µg/mL to 0.125 µg/mL, and from 0.06 µg/mL to 0.5 µg/mL for azithromycin (Table 3) .
Safety and Tolerability
In general, single-dose therapy with solithromycin did not lead to adverse events that limited medication use. There were no deaths, serious adverse events, or study withdrawals related to solithromycin. The most common treatment-associated adverse events were gastrointestinal in nature and appeared to be dose related (Table 4) . Self-limited, loose stools occurred in 17 of 28 (61%) participants who received the 1200-mg dose and 13 of 31 (42%) of those receiving 1000-mg doses. In all cases, the loose stools resolved spontaneously without intervention. Similarly, mild nausea and vomiting were more common in participants receiving the 1200-mg dose (32% and 14%, respectively) than the 1000-mg dose (26% and 3%, respectively). Among the participants who reported vomiting, this typically occurred an hour or more after ingestion of solithromycin. Although no participant had changes in laboratory evaluations that were considered to be clinically significant, in 1 participant receiving 1200 mg of solithromycin, the baseline total bilirubin increased from 1.4 mg/dL to 3.2 mg/dL before declining, with direct bilirubin never exceeding 0.4 mg/dL.
DISCUSSION
The development of resistance to the antimicrobial agents recommended for treatment of gonococcal infections is a longstanding and well-recognized problem. In recent years, this problem has been exacerbated by the dwindling numbers of new antimicrobials available for gonorrhea treatment, making development and evaluation of new drugs for gonorrhea therapy a global public health priority. In this study, either of 2 oral doses of solithromycin, a fourth-generation macrolide and the first fluoroketolide, were 100% effective for eradication of culture-proven uncomplicated gonorrhea detected at urogenital sites, the oropharynx, and the rectum. In an era in which progressive antimicrobial resistance has now reduced recommended therapies for gonorrhea treatment to a single regimen consisting of an intramuscular injection of ceftriaxone combined with a single oral dose of azithromycin, highly effective oral medications unrelated to β-lactam antimicrobials represent an exciting potential step forward. The fact that solithromycin can be given orally rather than requiring parenteral administration expands the potential utility of this drug and adds further to the appeal of this potential new therapy. Mechanistically, like other macrolide antimicrobials, solithromycin is active at the bacterial ribosome, reshaping the cellular proteome and not only arresting cellular metabolism through curtailment of protein synthesis but also leading to production of nonfunctional peptides that block the bacterial ribosomal tunnel to make the drug effect bactericidal rather than bacteriostatic, as is the case for most macrolides. Moreover, the fact that solithromycin, unlike most other macrolides, is active at multiple sites on the bacterial ribosome is another feature that could potentially represent a relative barrier to development of antimicrobial resistance.
To provide data reflecting the emergence of NAATs as the preferred tests for diagnosis of gonococcal and chlamydial infections at both genital and extragenital sites of infection, we tested all participants at enrollment with NAATs and tested those with positive tests at the time of follow-up 7-10 days following therapy. Reflecting the greater sensitivity of NAATs for detecting extragenital infections, using NAATs allowed us to identify additional extragenital infections among our study participants not detected by culture. At follow-up and despite the tendency for NAATs to remain positive following effective therapy [15, 16] , about 87% of positive gonococcal NAATs had also reverted to negative by the time of follow-up testing, further validating the efficacy of solithromycin for treatment of gonorrhea.
Patients with gonococcal infection are often coinfected with other pathogens such as C. trachomatis or M. genitalium. In this study, chlamydial coinfection was detected in 11 of the 59 (19%) participants. Of these, only 2 (18%) were positive at the time of follow-up after single-dose solithromycin therapy (Table 2) . Similarly, following single-dose solithromycin therapy, M. genitalium nucleic acids were detected in the urine of just 3 of 10 participants whose tests were initially positive. Despite small numbers and the fact that this study was not designed to evaluate clearance of these infections following solithromycin therapy, these preliminary data add to in vitro data indicating activity against these pathogens [12, 13, 17] , and suggests that the drug may be efficacious for these sexually transmitted infections as well.
Solithromycin was relatively well tolerated in this phase 2 study. Our data suggest a dose-related gastrointestinal toxicity of the drug; however, these mild side effects (nausea, loose stool, vomiting) did not appear to impact the efficacy of the drug. Interestingly, when nausea and vomiting were noted, they occurred about an hour after ingestion of the antibiotic, at which time the drug had already been absorbed, unlike the older macrolide azithromycin, where nausea and vomiting generally occurs soon after ingestion.
Our study was a phase 2 trial and thus should be considered to be preliminary. Further, none of the gonococci isolated from study participants had high-level macrolide resistance, a problem that is becoming increasingly common in some parts of Europe. Despite these limitations, our data suggest that solithromycin is highly effective for treatment of gonorrhea, including infections occurring at sometimes difficult-to-treat extragenital sites such as the pharynx and rectum. Furthermore, the apparent activity of single-dose solithromycin therapy for chlamydial and M. genitalium coinfection suggests that additional, larger studies are warranted to evaluate the efficacy of solithromycin for gonorrhea therapy.
Notes
